Market Research Logo

Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018

Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018

Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018, report provides comprehensive Insight about pipeline drugs along with technologies involved across this mechanism. The report provides the detailed analysis of 80+ products along with 45+ companies involved. Memgen has been granted Orphan drug designation from US-FDA for ISF 35 for the treatment of stage IIb through IV melanoma.
Products covered by Phase
• Phase II and Phase I
• Pre-clinical and Discovery
• Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Immune Checkpoints Activators
Pipeline analysis of 80+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Immune Checkpoints Activators
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
• The report provides competitive pipeline landscape of Immune Checkpoints Activators
• The report provides the marketed drugs information including its sales, development activities and details of patent expiry
• The report provides the insight of current and future market for Immune Checkpoints Activators
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling
• Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy
• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
• Establish a comprehensive understanding of the current pipeline scenario across Immune Checkpoints Activators to formulate effective R&D strategies
• Assess challenges and opportunities that influence Immune Checkpoints Activators R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Devise corrective measures for pipeline projects by understanding Immune Checkpoints Activators pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Immune Checkpoints Activators to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Immune Checkpoint Activators Overview
Rationale for targeting Immune checkpoint Agonist in oncology
Stimulatory checkpoint molecules
Advantages of Immune checkpoint Activators
Constraints of Immune Checkpoint Activators
Competitive Landscape
Collaborations and Deal values
Licensing Opportunities
Companies Investment Details for Future Development
Pipeline Therapeutics
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
NKTR-214: Nektar Therapeutics
Product Description
Research and Development
Product Development Activities
(The list continues)
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical Stage Products
Comparative Analysis
Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products
Comparative Analysis
Market Drivers and Barriers
List of Tables and Figures
Table 1:Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 2: Licensing Opportunities
Table 3: Investment Details
Table 4: Total Products for Immune Checkpoint Activators
Table 5: Mid Stage Products (Phase II)
Table 6: Early Stage Products (Phase I)
Table 7: Pre-clinical Stage Products
Table 8: Discovery Stage Products
Table 9: Assessment by Monotherapy Products
Table 10: Assessment by Route of Administration
Table 11: Assessment by Stage and Route of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Dormant and Discontinued Products
Figure 1: Types of Immune Checkpoint receptors
Figure 2: Total Products for Immune Checkpoint Activators
Figure 3: Mid Stage Products (Phase II)
Figure 4: Early Stage Products (Phase I)
Figure 5: Pre-clinical Stage Products
Figure 6: Discovery Stage Products
Figure 7: Assessment by Monotherapy Products
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Dormant and Discontinued Products

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report